Yabao Pharmaceutical Group Co., Ltd (SHA:600351)
China · Delayed Price · Currency is CNY 6.08
-0.10 (-1.62%)
Jun 11, 2026, 11:29 AM CST
SHA:600351 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,168 | 2,210 | 2,652 | 2,880 | 2,681 | 2,681 |
Other Revenue | 30.03 | 30.03 | 34.52 | 29.46 | 37.45 | 83.2 |
| 2,198 | 2,240 | 2,686 | 2,910 | 2,718 | 2,764 | |
Revenue Growth (YoY) | -13.12% | -16.60% | -7.69% | 7.05% | -1.66% | 6.21% |
Cost of Revenue | 1,070 | 1,092 | 1,323 | 1,246 | 1,216 | 1,095 |
Gross Profit | 1,128 | 1,148 | 1,363 | 1,664 | 1,502 | 1,669 |
Selling, General & Admin | 670.95 | 689.56 | 913.51 | 1,228 | 1,159 | 1,296 |
Research & Development | 114.05 | 117.27 | 139.52 | 118.29 | 130.62 | 157.13 |
Other Operating Expenses | 29.67 | 31.14 | 31.05 | 31.34 | 33.98 | 33.38 |
Operating Expenses | 811.07 | 837.45 | 1,086 | 1,373 | 1,324 | 1,473 |
Operating Income | 316.45 | 310.77 | 277.18 | 291.5 | 178.07 | 196.65 |
Interest Expense | -1 | -1.46 | -5.35 | -12.3 | -18.77 | -22.61 |
Interest & Investment Income | 79.17 | 79.05 | 6.45 | 9.49 | 8.18 | 22.04 |
Currency Exchange Gain (Loss) | -0.07 | -0.07 | 0.05 | -0.03 | 0.27 | -0.13 |
Other Non Operating Income (Expenses) | 7.36 | 7.46 | 5.96 | -9.75 | -8.01 | -3.53 |
EBT Excluding Unusual Items | 401.91 | 395.77 | 284.29 | 278.91 | 159.74 | 192.42 |
Impairment of Goodwill | - | - | - | - | -48.3 | - |
Gain (Loss) on Sale of Investments | 4.49 | 19 | -3.04 | -5.35 | -4.17 | 1.34 |
Gain (Loss) on Sale of Assets | 0.29 | 0.34 | 0.35 | 1.12 | 0.12 | 0.15 |
Asset Writedown | -59.79 | -64.26 | -27.53 | -84.97 | -9.75 | -22.97 |
Other Unusual Items | 24.01 | 23.61 | 38.04 | 29.26 | 28.02 | 30.66 |
Pretax Income | 370.9 | 374.46 | 292.11 | 218.98 | 125.65 | 201.59 |
Income Tax Expense | 70.1 | 74.56 | 68.19 | 39.07 | 21.04 | 17.83 |
Earnings From Continuing Operations | 300.8 | 299.9 | 223.92 | 179.91 | 104.6 | 183.76 |
Minority Interest in Earnings | 18.6 | 20.11 | 18.77 | 19.67 | 0.05 | 3.33 |
Net Income | 319.41 | 320.01 | 242.69 | 199.59 | 104.66 | 187.09 |
Net Income to Common | 319.41 | 320.01 | 242.69 | 199.59 | 104.66 | 187.09 |
Net Income Growth | 34.38% | 31.86% | 21.60% | 90.71% | -44.06% | 74.25% |
Shares Outstanding (Basic) | 696 | 699 | 723 | 763 | 770 | 770 |
Shares Outstanding (Diluted) | 696 | 699 | 723 | 763 | 770 | 770 |
Shares Change (YoY) | -2.72% | -3.29% | -5.25% | -0.89% | 0.02% | -0.04% |
EPS (Basic) | 0.46 | 0.46 | 0.34 | 0.26 | 0.14 | 0.24 |
EPS (Diluted) | 0.46 | 0.46 | 0.34 | 0.26 | 0.14 | 0.24 |
EPS Growth | 38.14% | 36.35% | 28.34% | 92.42% | -44.07% | 74.32% |
Free Cash Flow | 573.06 | 524.91 | 437.03 | 397.7 | 398.23 | 342.45 |
Free Cash Flow Per Share | 0.82 | 0.75 | 0.60 | 0.52 | 0.52 | 0.45 |
Dividend Per Share | 0.350 | 0.350 | 0.300 | 0.150 | 0.050 | 0.080 |
Dividend Growth | 16.67% | 16.67% | 100.00% | 200.00% | -37.50% | 60.00% |
Gross Margin | 51.31% | 51.26% | 50.73% | 57.19% | 55.27% | 60.39% |
Operating Margin | 14.40% | 13.87% | 10.32% | 10.02% | 6.55% | 7.12% |
Profit Margin | 14.54% | 14.29% | 9.04% | 6.86% | 3.85% | 6.77% |
Free Cash Flow Margin | 26.08% | 23.43% | 16.27% | 13.67% | 14.65% | 12.39% |
EBITDA | 449.52 | 444.5 | 413.52 | 447.11 | 338.04 | 363.93 |
EBITDA Margin | 20.46% | 19.84% | 15.39% | 15.37% | 12.44% | 13.17% |
D&A For EBITDA | 133.08 | 133.73 | 136.34 | 155.61 | 159.97 | 167.27 |
EBIT | 316.45 | 310.77 | 277.18 | 291.5 | 178.07 | 196.65 |
EBIT Margin | 14.40% | 13.87% | 10.32% | 10.02% | 6.55% | 7.12% |
Effective Tax Rate | 18.90% | 19.91% | 23.34% | 17.84% | 16.75% | 8.85% |
Revenue as Reported | 2,198 | 2,240 | 2,686 | 2,910 | 2,718 | 2,764 |
Advertising Expenses | - | 115.73 | 130.74 | 119.31 | 105.5 | 100.49 |